Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, Jacques Azzi, Brenda W Cooper, Abhinav Deol, John DiPersio, Divya Koura, Brian McClune, Lori S. Muffly, Muhammad Umair Mushtaq, Rupa Narayan, Hyung Chan Suh, Gregory Yanik, Sritama Nath, Jennifer Whangbo, Guenther Koehne

Blood (2023) 142 (Supplement 1): 4862.

https://doi.org/10.1182/blood-2023-180990

Published: 2023

Journal Articles

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Brian T. Hill, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Robert M. Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison Winter, Ethan Krauspe, Jonathan Zhou, Taylor R. Brooks, Merve Kacar, Ben K. Tomlinson, Brenda W Cooper, Hong Li, Xuefei Jia, Yanwen Chen, Jenna Thomas, Paolo F. Caimi

Blood (2023) 142 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2023-173943

Published: 2023

Journal Articles

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Brenda W Cooper, Molly Megan Gallogly, Leland Metheny, Rebecca B. Klisovic, Kirsten Marie Boughan, Jane Reese Koc, Darong Wu, Changchun Deng, Koen Van Besien, Rose Tupta, Dina Schneider, Lisa Ciarrone, Marcos de Lima, Paolo F. Caimi, Benjamin K. Tomlinson

Blood (2023) 142 (Supplement 1): 6872.

https://doi.org/10.1182/blood-2023-191153

Published: 2023

Journal Articles

Incidence and Outcomes of Pneumocystis Pneumonia Following Chimeric Antigen Receptor T-Cell Therapy: A Real-World Analysis

Jiasheng Wang, Michael Daunov, Brenda W Cooper

Blood (2023) 142 (Supplement 1): 6897.

https://doi.org/10.1182/blood-2023-190785

Published: 2023

Journal Articles

Assessing the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in Risk-Stratifying Multiple Myeloma Patients for Autologous Stem Cell Transplantation

Jeries Kort, Sathya Sri Areti, Nikolas Naleid, Brenda W Cooper, Ehsan Malek

Blood (2023) 142 (Supplement 1): 6706.

https://doi.org/10.1182/blood-2023-190931

Published: 2023

Journal Articles

Dynamics and Predictive Value of T-Cell Chimerism after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

Jiasheng Wang, Benjamin Tomlinson, Ehsan Malek, Leland Metheny, Molly Gallogly, Marcos de Lima, Merle Kolk, Brenda W. Cooper

Blood (2022) 140 (Supplement 1): 12831–12832.

https://doi.org/10.1182/blood-2022-163589

Published: 2022

Journal Articles

Retrospective Comparison of Patients with Chronic Lymphocytic Leukemia Receiving BTK Inhibitors Versus Obinutuzumab/Venetoclax As Frontline Therapy

Jiasheng Wang, Srilatha Dasari, Michael Daunov, Kanithra Sekaran, Yeseong Kim, Brenda W. Cooper

Blood (2022) 140 (Supplement 1): 9889–9890.

https://doi.org/10.1182/blood-2022-167875

Published: 2022

Journal Articles

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

Paolo F Caimi, Martina Di Trani, Armin Ghobadi, Jane Reese, Benjamin Tomlinson, Folashade Otegbeye, Kirsten M Boughan, Molly Gallogly, Leland Metheny, Brenda W. Cooper, Boro Dropulic, Marcos J.G. de Lima, Carmelo Carlo-Stella

Blood (2022) 140 (Supplement 1): 7457–7459.

https://doi.org/10.1182/blood-2022-170629

Published: 2022

Journal Articles

Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Leland Metheny, Ronald M. Sobecks, Christina Cho, Jiasheng Wang, Lisa Ciarrone, Paolo F. Caimi, Folashade Otegbeye, Brenda W. Cooper, Molly Gallogly, Ehsan Malek, Aaron T. Gerds, Betty K. Hamilton, Sergio A Giralt, Miguel-Angel Perales, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 1887–1889.

https://doi.org/10.1182/blood-2022-169935

Published: 2022

Journal Articles

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Brenda W. Cooper, Hyung C. Suh, Divya Koura, Guenther Koehne, Christina Cho, Nadia M. Bambace, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Sritama Nath, Melissa M. Lee-Sundlov, Ali Lacy, Darren Stanizzi, Karen Kuhn, Jennifer S. Whangbo, Christopher Slapak, Glen D. Raffel

Blood (2022) 140 (Supplement 1): 12973–12975.

https://doi.org/10.1182/blood-2022-165289

Published: 2022

Journal Articles

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Sarit Assouline, Amitkumar Mehta, Tycel Phillips, Lapo Alinari, Alexey V. Danilov, Stéphane Doucet, Steven I. Park, Deborah Berg, Alejandro Gomez-Pinillos, Alonzo Martinez, Bo Chao, Allison J Berger, John Gibbs, Sharon Friedlander, Christine K. Ward, Igor Proscurshim, Brenda W. Cooper, Paolo F Caimi

Blood (2021) 138 (Supplement 1): 2488.

https://doi.org/10.1182/blood-2021-152225

Published: 2021

Journal Articles

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Leland Metheny, III, Ronald M. Sobecks, Christina Cho, Paolo F. Caimi, Navneet S. Majhail, Folashade Otegbeye, Kirsten M Boughan, Brenda W. Cooper, Erin Galloway, Molly Gallogly, Ehsan Malek, Benjamin Tomlinson, Aaron T. Gerds, Betty K. Hamilton, Matt Kalaycio, Sergio A Giralt, Marcos J.G. de Lima

Blood (2021) 138 (Supplement 1): 2899.

https://doi.org/10.1182/blood-2021-153041

Published: 2021

Journal Articles

Development of a Risk Score for Cardiovascular Events in Anthracycline Treated DLBCL Patients

Akiva Diamond, Sabarish Ayyappan, Shufen Cao, Nour Tashtish, Kirsten M Boughan, Brenda W. Cooper, Pingfu Fu, Paolo F. Caimi

Blood (2021) 138 (Supplement 1): 2536.

https://doi.org/10.1182/blood-2021-153862

Published: 2021

Journal Articles

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Blood (2021) 138 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2021-151155

Published: 2021

Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137685

Published: 2020

Journal Articles

Results of a Phase I Trial of Lenalidomide, Rituximab (R 2 ) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Brian T. Hill, MD, Deepa Jagadeesh, MDMPH, Alex V. Mejia Garcia, MD, Robert M. Dean, MD, Omer N. Koc, MD, Matt Kalaycio, MD, Kirsten M Boughan, DO, Brenda W. Cooper, MD, Allison M. Winter, MD, Wesam B. Ahmed, MD, Brad Pohlman, MD, Christopher D'Andrea, PA-C, Kelsey Holkovic, RN, Ashley Morrison, RN, Paolo Caimi, MD, Mitchell Smith, MDPhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136370

Published: 2020

Journal Articles

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Naveed Ali, MD, Ana Carolina Pires de Rezende, MD, Folashade Otegbeye, MBBChir,MPH, Mariana Nassif Kerbauy, MD, Brenda W. Cooper, MD, David Mansur, MD, Gisele Pereira, PhD, Roberto Sakuraba, MD, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Cinthya Correa Silva, MD, Leland Metheny, III, MD, Andreza Feitosa Ribeiro, MD, Molly M Gallogly, MDPhD, Ehsan Malek, MD, EDuardo Weltman, MD, Marcos de Lima, MD, Nelson Hamerschlak, MD PhD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142197

Published: 2020

Journal Articles

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Anna Eversman, Shufen Cao, Kirsten M Boughan, DO, Molly M Gallogly, MDPhD, Ehsan Malek, MD, Leland Metheny, III, MD, Timothy E. O'Brien, MD, Folashade Otegbeye, MBBChir,MPH, Brenda W. Cooper, MD, Pingfu Fu, Marcos de Lima, MD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140042

Published: 2020

Journal Articles

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Ehsan Malek, MD, Jeries Kort, MD, Gi-Ming Wang, PhD, Paolo F Caimi, MD, Kirsten M Boughan, DO, Stanton L. Gerson, MD, Brenda W. Cooper, MD, Molly M Gallogly, MDPhD, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Curtis Tatsuoka, PhD, James Driscoll

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-139733

Published: 2020

NARROW

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Incidence and Outcomes of Pneumocystis Pneumonia Following Chimeric Antigen Receptor T-Cell Therapy: A Real-World Analysis

Assessing the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in Risk-Stratifying Multiple Myeloma Patients for Autologous Stem Cell Transplantation

Dynamics and Predictive Value of T-Cell Chimerism after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

Retrospective Comparison of Patients with Chronic Lymphocytic Leukemia Receiving BTK Inhibitors Versus Obinutuzumab/Venetoclax As Frontline Therapy

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Development of a Risk Score for Cardiovascular Events in Anthracycline Treated DLBCL Patients

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Results of a Phase I Trial of Lenalidomide, Rituximab (R 2 ) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only